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ABSTRACT
The purpose of this study was to determine if human parathyroid hormone-(1-38) (VI'H)
can restore cancellous bone mass to the established osteopenic, immobilized proximal tibial
metaphyses (PTM) of female rats. The right hindlimbs of six-month-old female Sprague-Dawley
rats were immobilized by bandaging the fight hindlimbs to the abdomen. After 30 days of fight
hindlimb immobilization (RIB_,I), the rats were subcutaneously injected with 200 p.g hPTH(1-
38)/kg/day for 15 (short-term) or 75 (longer-term) days. Static bone histomorphometry was
performed on the primary spongiosa, while both static and dynamic histomorphometry were
performed on the secondary spongiosa ot_ the right PTM. Immobilization for 30 days without
treatment decreased trabecular bone area, number and thickness in both primary and secondary
spongiosa, and induced an increase in eroded perimeter and a decrease in tissue referent-bone
formation rate (BFR/TV) in the secondary spongiosa. These changes reached a new steady state
thereafter. Treatment with 200 I.tg hPTH(1-38)/kg/day for 15 days, beginning at 30 days post
immobilization (IM), significantly increased trabecular bone area, thickness and number in both
primary and secondary spongiosa despite continuous IM when compared to the age-related and IM
controls. The short-term (15 days) PTH treatment significantly increased labeling perimeter,
mineral apposition rate and BFR/TV in the secondary spongiosa and stimulated longitudinal bone
growth as compared to the age-related and IM controls. PTH treatment for longer-term (75 days)
further increased trabecular bone area, thickness and number as compared to aging and IM controls
and short-term (15 days) PTH treated groups. The bone formation indices in the secondary
spongiosa of these longer-term treated rats were lower than that of short-term (15 days) PTH
treated group, but they were still higher than those of IM and age-related controls. Our findings
indicate that PTH treatment stimulates cancellous bone formation, restores and adds extra
cancellous bone to the established, disuse-osteopenic proximal tibial metaphysis of continuously
RHLI female rats. These results suggest that PTH may be a useful agent in treating disuse-induced
osteoporosis in humans.
INTRODUCTION
In a recent review Dempster and his colleagues (1), found both a number of clinical studies
supporting the anabolic effect of parathyroid hormone (PTH). They reported that PTH alone or
combined with 1,25(OH)2D3 improved calcium and phosphate balance, increased serum
1,25(OH)2Da, stimulated bone formation and increased bone mass in postmenopausal osteoporotic
patients and elderly non-osteopenic women as well as in osteoporotic men (2-11). In animal
studies, PTH has been shown to stimulate bone formation and increase bone mass in intact male
and female rats (12-18), prevent bone loss induced by ovariectomy (16,19-23) or orchidectomy
(23), and restore bone to the osteopenic skeleton induced by ovariectomy (16,24-30),
parathyroidectomy (30), hemicordectomy (30) or lactation plus low-calcium diet (12). With these
encouraging clinical and prechnical findings, we postulate that PTH should restore cancellous bone
lost by immobilization. We used female rats with established LM-induced osteopenic skeleton to
investigate this hypothesis.
For this study we employed the right hindlimb immobilization (RHJ_,I) rat as an animal
model of disuse osteopenia. Several studies have found that significant bone loss in the right
hindlimb of RHLI rats occurred after only 1 week of immobilization, with this bone loss reaching a
new steady state after 4 weeks of immobilization (31-34). In the present study, 6-month-old
female rats were right hindlimb immobilized for 30 days to induce osteopenia, then treated with
human parathyroid hormone (hPTH(1-38)) plus RHLI for 15 and 75 days. These two time points
allowed us to assess the transient and steady state responses of the RHLI-induced osteopenic
skeleton to daily PTH administration.
MATERIALS AND METHODS
Sixty-three 6-month-old virgin female Sprague-Dawley rats weighing approximately 257 g
(Simonsen Laboratory, Inc., Gilroy, CA) were acclimated to local vivarium conditions (24°C and
12h/12h light-dark cycle) for 7 days. During the experimental period, the rats were allowed free
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accessto waterandpelletedcommercialnaturalproductdiet (TekladRodentChow#8604,Harlan
Teklad,Madison,WI), whichcontains1.46%calcium,0.99%phosphorus,and4.96 IU/g Vit D3.
Ratsweredivided into fourmain groupsandthensubdividedinto ninestudygroups(6 to 7 rats
persubgroup).Thesegroupswere: (I) Age-relatedcontrolsat days0, 30,45and 105;(IT)Right
hindlimb immobilization(RHLI) controlsat days30,45and105;(III) RHLI for thefirst 30days,
and thenRHLI plus subcutaneousinjectionsof 200 gg hPTH(1-38)/kg/dayfor another 15days
(sacrificed at experimentalday 45); (IV) RHLI for the first 30 days, and then RHLI plus
subcutaneousinjections of 200 I.tg hPTH(1-38)/kg/day for another 75 days (sacrificed at
experimentalday 105)(TableI). °
Theright hindlimbwas boundto theabdomenwith elasticbandages.Four layersof this
placed thehip joint in flexion and the kneeand ankle joints in extension. The bandagewas
checkeddailyandreplacedtwiceweekly(31-34). In thismodel,the fight hindlimb is underloaded
during ambulation.
We prepared our treatment solution from powdered hPTH(1-38) supplied by Bachem Co.,
(Torrance, CA). We dissolved in vehicle (100 ml: 192.1 mg citric acid, 331.2 mg Na2HPO4,
764.0 mg NaC1), and then adjusted the volume to desired concentrations. We prepared each dose
daily by freezing the appropriate volume at -20°C. The rats in the PTH treated groups were
subcutaneously injected with 200 gg hPTH(I-38) daily (0.5 ml/kg), while the rats in the age-
related and immobilized control groups were injected with vehicle (0.5 ml/kg). The dose selected
was based on the findings of Gasser and Jerome (16). The rats were weighed weekly and the
volume of the injection solution was adjusted accordingly.
All rats were triple labeled. They received an injection of 90 mg/kg of Xylenol Orange
(Sigma Chemical Co., St. Loluis, MO) on day 30, and 25 mg/kg of Achromycin tetracycline
hydrochloride (Lederle Laboratory, Pearl River, NY) at 14 and 13 days and 10 mg/kg of Calcein
(Sigma Chemical Co., St. Louis, MO) at 4 and 3 days before sacrifice. The day 30 injection of
Xylenol Orange was given to fluorochrome label the mineralized surface before PTH treatment
(Fig. 2F).
Theratswere sacrificedunderketaminehydrochlorideandxylazineanesthesiaviacardiac
puncture. The gastrocnemiusandsoleusmuscleswereremovedand weighed. The right tibiae
wereremoved,dissectedandcut into threeequalparts. The proximal tibiaewerefixed in 10%
phosphatebufferedformalin(24 to 48hrs),50and70%ethanolof 24hrseachto removeformalin
andstain in Villanueva osteochromestain (35); (PolyscienceInc., Warrington,PA) for 5 days.
Theboneswerethendehydratedin gradedalcoholsandseveralchangesof acetoneandembedded
in methylmethacrylate.Frontalsectionsof 220 gm werecutwith anIsometsawandgroundto 20
/.tin. These 20 gm undecalcified sections were used for static and dynamic histomorphometric
measurements as previously described (36-58).
A Digitizing Image Analysis System (DIAS) was used to determine the trabecular bone
mass (the percept of trabecular bone area) and structural indices (the trabecular bone number and
thickness) in both. primary (1 mm to the growth plate-metaphyseal junction) and secondary
(between 1 and 4 mm distal to the growth plate-metaphyseal junction) spongiosa of the proximal
tibial metaphyses (36). We also measured the dynamic histomorphometric indices in the secondary
spongiosa. These measurements included the trabecular eroded perimeter, osteoid perimeter,
single-labeled perimeter, double-labeled perimeter, and interlabeling width. These measurements
were used to derive indices of the percent of the osteoid perimeter, eroded perimeter, and labeled
perimeter (double plus one-half single label), and mineral apposition rate, bone formation rate
(bone area and tissue area referent), and longitudinal growth rate (37-41).
There was about 10 gin/day of longitudinal bone growth in the 6-month-old rats, and about
5 I.tm/day in the 9.5-month-old rats; therefore, after 75 days approximately 0.6 mm of new
metaphysis was generated on the proximal tibia (42). By defining the primary spongiosa as that
region from the growth plate-metaphyseal junction distal to 1 man (36) and the secondary
spongiosa within the area from 1 mm to 4 mm from the growth plate metaphyseal junction was
analyzed. Histomorphometric measurements in the secondary spongiosa were performed on
cancellous bone that was predominately remodeling and treated during the treatment period (36).
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We wereableto performonlystaticmorphometricmeasurementsin theprimaryspongiosabecause
theremodelingpredominatedandwovenbonethat formedwasdiffuselylabeled(36,43).
Thedifferencesamonggroupmeansat eachtimeperiodwereevaluatedusingananalysis
of variance(ANOVA) andtheFisherPLSDtest(44). Thedifferencesbetweenthemeansfrom the
differenttimeperiodswereanalyzedusingatwo-tailedStudent'st-test. A probabilitylessthan
< 0.05wasconsideredsignificant.
RESULTS
Effects on Body Weight and Muscle" Weight.
The age-related control rats gained body weight steadily during the experimental period.
By days 30 and 45, the RHLI control rats had lost weight compared to age-related controls, but
this loss was moderated by day 105. Body weight in the PTH-treated RHLI rats did not differ
from that of the immobilization (IM) controls at day 45, and was significant higher than the I5,I
controls and did not differ from the age-related controls by day 105 (Table 1).
There were no significant differences in either gastrocnemius or soleus muscle weights
between basal and the age-matched controls (Table 1). However, both gastrocnemius and soleus
muscle weights in the immobilized limbs decreased significantly compared to those of the age-
related controls at all experimental time points. However, the muscle weights in the PTH-treated
immobilized limbs did not significantly differ from vehicle-treated 12Vlcontrols (Table 1).
Effects on Longitudinal Bone Growth Rate.
The longitudinal growth rate (LGR) in the proximal tibia significantly decreased with age,
from 7.9_+0.4 l.tm/day at 6 months (day 0) to 4.6_+0.3 p.m/day at 9.5 months of age (day 105)
(Table 1). There was no difference in LGR between IM and age-related controls. After both 15
and 75 days of treatment, the LGR was significantly greater in the IM, PTH-treated proximal tibial
than that of IM controls (Table 1).
Qualitative Observation of Proximal Tibial Metaphyseal Cancellous Bone
In the proximal tibia/metaphysis (PTM) of the age-related control rats, the growth plate
gradually thinned, while trabeculae gradually thickened with age (Figs. 1 d vs. a,b,c).
In the immobilized PTM, there was less cancellous bone mass, the trabeculae were thinner
and fewer, especially in the primary spongiosa and in the junctional area of the primary and
secondary spongiosa (Figs. 1 e, f, g vs. b, c, d). There was less double labeled surface (Figs. 2B
vs. A) and the interlabeled distance was narrower in the immobilized PTM than in the age-related
controls (Fig. 2 E vs. D).
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In the 15-day-PTH-treated immobilized PTM, the cancellous bone mass was greater and
the trabeculae in the primary and secondary spongiosa were thicker than in either IM or the age-
related controls (Figs. 1 h vs. f and c). Cancellous bone mass continued to increase in the PTH-
treated immobilized PTM for 75 days (Figs. 1 i vs. h; i vs g and d). Massive new bone formation
was found in the PTH-treated immobilized PTM (Figs. 2 C vs. B and A). We deduced the bone
formed by the PTH treatment was not involved in bone resorption because bone labeled with
xylenol orange at the start of PTH treatment persisted (Figs. 2 F vs. D and E). Thus, a large
portion of the new cancellous bone was deposited without prior bone resorption (Fig. 2 F).
Effects on Static histomorphometry of Proximal Tibial Metaphyseal Primary
Spongiosa
Between 6 and 9.5 months of age, the trabecular bone area remained unchanged.
However, there were other changes during this period. Trabecular number decreased -18% while
the trabecular thickness increased +18% (Table 3 and Fig. 3).
Immobilization also induced significant decreases in trabecular bone area (-51%), thickness
(-19%), and number (-39%) by day 30, and these parameters plateaued thereafter (Table 3 and
Fig. 3).
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In 15 day PTH-treated immobilized PTM, trabecular bone area (+51% and +249%),
thickness (+30% and +81%) and number (+ 17% and +95% ) increased significantly as compared
to the age-related and IM controls, respectively (Table 3 and Fig. 3). Further, PTH treatment for a
total of 75 days in the continuously immobilized PTM increased trabecular bone area (+115% and
435%), thickness (+58% and +114%) and number (+38% and +148%) as compared to the age-
related and IM controls, respectively (Table 3 and Fig. 3).
Effects on Static histomorphometry of Proximal Tibial Metaphyseal secondary
Spongiosa °
Except for a thicker trabecula in the 9.5 month old secondary spongiosa, there were no
significant bone mass or other architectural changes between 6 and 9.5 months of age.
Significant decreases, similar to those seen in the primary spongiosa, were found in the
secondary spongiosa after 30 days of IM. These decreases included a decline in trabecular bone
area (-30%), thickness (-9%), and number (-22%). After the 30 day period, these indices reached
a new steady state (Table 3 and Fig. 3).
Si_maificant improvement of the trabecular structure of secondary spongiosa appeared after
15 days of PTH treatment. When compared to the indices of the age-related and IM controls,
respectively, trabecular bone area (+66% of the age-related controls, and +252% of IM controls),
thickness (+39% of the age-related and +57% of IM controls), and number (+20% of the age-
related, and +59% of IM controls) all increased (Table 3 and Fig. 3). After the longer 75 days, the
treated groups showed further increases over age-related and IM controls, respectively, in bone
mass (+246% and +419%) and structural parameters (+190% and +240% in trabecular thickness,
+24% and +58% in trabecular number) (Table 3 and Fig. 3).
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Effects on Dynamic Histomorphometry of Secondary Spongiosa
Between 6 and 9.5 months of age, controls had significant decreases in percent labeling
perimeter (%L.Pm, -37%), mineral apposition rate (MAR,-61%), bone formation rate-tissue area
referent (BFRfTV, -75%) and bone formation rate-bone area referent (BFR/BV,-78%), while there
was no change in percent eroded perimeter (%Er.Pm) (Table 4 and Fig. 4).
Significant decreases in MAR (-53%), BFRffV (-70%) and BFR/BV (-54%), and a
significant increase in %Er.Pm (+34%) occurred in the immobilized PTM as compared to the age-
related controls after 30 days of IM (Tabl_ 4 and Fig. 4). At day 45, the significant differences
between IM and the age-related controls were limited to a decrease in BFR/TV (-33%) and an
increase in %Er.Pm (+96%). All dynamic indices listed in Table 4 and Figure 4 reached a new
steady state after 105 days of IM (Table 4 and Fig. 4).
Immobilized rats treated with PTH for 15 days significantly increased %L.Pm (+95% and
+91%), %O.Pm (+247% and +235%), MAR (+59% and 84%), BFR/TV (+271% and +457%)
and BFR/BV (+121% and +121%),when compared to IM and age-related controls. Percent
eroded surface was higher than age-related controls while not different from IM controls (Table 4
and Fig. 4). Percent labeled perimeter (+81% and +77%), %O.Pm (+256% and +206%), MAR
(+17% and +13%) and BFR/TV (+152% and +211%) increased significantly, and BFRfBV (-36%
of IM controls) decreased significantly in the 75 days of PTH treated rats as compared to the age-
related and IM controls, respectively. Percent eroded perimeter in the 75 days PTH-treated rats did
not differ from that of age-related and IM controls (Table 4 and Fig. 4).
DISCUSSION
The strategy for preventing and treating osteopenia has been based on two approaches: I)
inhibiting bone resorption with anti-resorptive agents and 2) stimulating bone formation with
anabolic agents. The effects of anti-resorptive agents in depressing bone resorption and slightly
increasing bone in women, for example estrogen (45-47), bisphosphonates (48-50), calcitonin
(51-52)andcalcium (53),haveprovenbeneficial. In animalexperiments,theseanti-resorptive
agentsalsopreventedovariectomy-or IM-inducedosteopenia(54-56). However,the useof anti-
resorptiveagentsin restoringthe lost bone in the low turnoverosteopenicskeletonhasbeen
discouraging(28). Theuseof boneanabolicagentsto stimulateboneformationand restorethe
lost bone appearsto be a better choice to treat establishedosteoporosis. In this study, we
successfullyrestoredcancellousboneto theIM-inducedosteopenicproximaltibial metaphysisof
ratswith humanparathyroidhormone-(1-38).
In this study, we examinedthe transientand steadystateskeletalresponses.Initially,
immobilizationinducedcancellousbonelossby suppressingboneformationandstimulatingbone
resorption. Later, the lossin trabecularbonemassreacheda new steadystateafter 30 daysof
immobilization,andboneresorptionandformationparametersreturnedto theage-relatedcontrol
levelsby day105. Thesefindingsarein agreementwith ourpreviousfindings(31-34)andFrost's
mechanostattheory (57-60).
The detailed mechanismof IM-induced boneloss remainsunknown. Thompson and
Rodan(61) found thatindomethacin,an inhibitor of prostaglandinsynthesis,preventedtheIM-
induced bone loss, which suggeststhat the increase in endogenousprostaglandinplays an
importantrole in stimulatingboneresorption.More recently,it wasfoundthatIM causesarapid
declinein parathyroidhormone-relatedprotein (PTHrP)mRNA expression(62). This suggests
that PTHrPplays a role in thedeclineof boneformation inducedby IM. Takentogether,these
findingssuggesthatthemechanismfor IM-inducedbonelossmustbedueto multiple factorsand
requiresmuchmorestudy.
Also in the presentstudy, we compared the different responsesof proximal tibial
metaphysealprimary andsecondaryspongiosato IM in femalerats. After 30 daysof IM, the
primary spongiosalost 51%of its trabecularbonemass,while thesecondaryspongiosalost less,
only 31%. It wassurprisingto find thatthepositivebonebalanceresponsewasthe sameat the
primaryandsecondaryspongiosain PTHtreatedRHLI rats(Table3). Their final trabecularbone
massin both areaswasabout60%. One would expect that the more active primary spongiosa
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wouldhavebeenmoreresponsive.Thesefindingsledusto postulatethattheability of theprimary
spongiosato respondwas dampenedby its high boneturnover rate (i.e. bone modeling and
remodeling rates) making less osteoblastprogenitorsavailable than those in the secondary
spongiosato reactto PTHtreatment.
We demonstratedthat PTH not only cancompletelyrestorebut over-replacecancellous
bonemassto theosteopenic,continuouslyimmobilizedproximaltibial metaphysis.After 15days
of PTHtreatment.,all boneformationparametersincreased ramatically.Theincreasesin labeled
perimeter,mineralappositionrateandboneformationratessuggesthatboth therecruitmentand
activity of osteoblastswereenhanced. Slnce the erodedperimeter,a bonesurface resorption
index,wasnot alteredby PTHtreatment,theoverallincreasesresultedin apositivebonebalance.
Although theboneformationparametersfell from their 15daytreatmentlevel after 75 daysof
treatment,theywerestill higherthanthoseof age-relatedandIM controls. The15day levelwas4
timesthatof thecontrolsandthe 75daylevel wasstill 2.5 timesgreaterthanthat of thecontrols.
Thedeclineof boneformationparametersafter75daysof PTHtreatmentremainsunexplained.
Theeffectof intermittentPTH injectionson boneresorptionis harderto define. Previous
measurementsof osteoclastnumber and surfacehavereportedeither increases(21), remain
unchanged(25,27),or decreases(20). Wronski etal. (28)comparedtheresponsesof ovariectomy
(OVX) withOVX ratsin earlystagesof PTHtreatment.Theyfoundthatin theOVX controls,the
boneformationrateincreased.Therewasnodifferencein theosteoclastsurfaceat 35days,butby
105days,theosteoclastsurfaceincreased.However,duringthesameperiod,boneformationrate
declined. In contrast,our studyshowedthat the 15dayand75 daysof PTH treatmentsdid not
alter the erodedsurfacewhen comparedto thoseof IM controls. The earlier depressionof
resorptionandcontinuedstimulatedboneformationcreatedapositivebonebalanceandmarked
augmentationof bonemasshaPTH-treatedimmobilizedproximaltibial metaphysis(PTM).
This study found that PTH treatment stimulated longitudinal bone growth in the
immobilizedPTM. This samefindinghasalsobeenreportedfor PTH-treatedovariectomizedrats
(28). PTH-stimulatedlongitudinalbonegrowthmayhavecontributed,at leastin part, to agreater
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cancellousbonemassespeciallyin theprimary spongiosa.This hypothesisis supportedby the
findingsin thechickgrowthplateculturestudyof Crabbet al.,wherePTH dramaticallyincreased
thymidineincorporationandthesynthesisof proteoglycan(63). Theseresultssuggestapossible
regulatoryrolefor PTH in endochondralossification.
In conclusion,our f'mdingsindicatethatPTH is a powerful anabolicboneagentthatcan
overcomedisuse-inducedboneloss. Theseresultsfurther suggesthatPTH maybe aneffective
treatmentfor disuse-inducedosteopeniain humans.
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Fig.4
FIGURE LEGENDS
Microphotographsof proximal tibial metaphysesfrom theage-relatedcontrols at 6 (a), 7
(b), 7.5 (c) and9.5(d) monthsof age,immobilizationcontrols(I.M)at days30 (e), 45 (f)
and 105(g), and200gg PTH/kg/day treatedimmobilizationproximal tibial metaphysis
(LM+PTH)at 15(h)and75 (i) dayspost-treatment.Seetext for explanation.X 4.
Microphotographsof proximaltibial metaphyses(PTM)andrepresentativetrabeculaefrom
thesecondaryspongiosaof theage-relatedcontrols(A andD), immobilizationcontrols(B
andE),and200/.tgPTI4_/kffdaytreatedimmobilizedproximaltibia1metaphysisfor 75days
(C andF). CancellousbonemassWaslessandtrabeculaewere thinnerand fewer in the
immobilizationcontrol(B) thanin age-relatedcontrol(A). Greatercancellousbonemass
andthicker, densertrabeculaewereobservedin theprimary and secondaryspongiosaof
75-day-PTH-treatedimmobilizedPTM (C, F) thanin immobilized(B andE) andtheage-
relatedcontrols(A andD). Therewasmoredoublelabeledtrabecularsurfaceandawider
interlabeldistancein the75-day-PTH-treatedimmobilizedPTM (C,F) thanin immobilized
(B andE) andtheage-relatedcontrols(A andD). Xylenol orange(XO), which wasgiven
to all ratsat theonsetof PTH or vehicleadministration,andtetracyclineandcalcein (DL)
werefoundin PTH-treatedimmobilizedPTM (F),whileonly tetracyclineandcalcein(DL)
canbe found in theage-related(D) andimmobilized(E)controls. Magnifications:A - C,
X12; D - F, X100.
Trabecularboneareachangesinprimary (ZoneI, A) andsecondary(ZoneII, B) spongiosa
of theage-relatedcontrols(aging),the immobilizationcontrols(IM) andthePTH-treated
immobilizedproximaltibial metaphysis(IM+PTH). *: p < 0.05vs.basal;#: p < 0.05vs.
aging;@:p < 0.05vs.IM.
Erodedperimeter (A), labeling perimeters(B), mineral appositionrate (C) and bone
formation rate-tissuereferent (D) changesin secondaryspongiosaof the age-related
controls (aging), the immobilization controls (IM) andthe PTH-treated immobilized
19
proximaltibial metaphysis(IM+PTH). *: p < 0.05vs.basal;#: p < 0.05vs.aging;@:p <
0.05vs. IM.
20
Table 1. Experimental Protocol
Experimental Day
Age of Rats (months)
0 30 45 105
6 7 7.5 10.5
AgSng Controls
IM Controls
IM+PTH
7t............... 7 oo...ooo....7---------.--.--.--------7
•o.o----.-oo---oo7 v v v v v v v v 7 v v v v v v v v v v v v v v v v 6
.o.............oo___7_ _ ____7
t: number of rats will be autopsied; • no treatment; oooo: vehicle treatment; .-......fight
hindlimb immobilization (IM) plus no treatment; v v v: fight hindlirnb immobilization (IM) plus
vehicle treatment; .r..r..)._: fight hindlimb itkanobilization (IM) plus 200 _g_/k_day of hPTH-(1-38)
treatment.
Table 2. Changes in Body Weight, Muscle Weight and Longitudinal Growth Rate
Groups
Day 0
Basal Controls
Body Muscle Weight Longitudinal
Weight Gastrocnemius Soleus Growth Rate
n (_) (_) (_) (_rn/day)
6 258±5.3 1.78±0.02 0.12±0.05 7.9±0.4
Day 30
Aging Controls 6 262±4.9 1.74±0.05 0.10±0.01 6.1 ±0.2 *
IMControls 6 252+6.1 *,# 0.67±0.0o, *,# 0.06'__.0.00*,# 4.7_4-0.2*
Day 45
Aging Controls 6 269 _ 5.7 1.81 ± 0.05 0.09 ± 0.01 5.8 ± 0.0 *
I
1MControls 6 252_+6.1 *,# 0.82±0.09 *,# 0.05__.0.01 *,# 4.6±0.2*
IM+PTH t 6 259 ± 5.7 0.69 ± 0.02 *,# 0.04 -+0.01 *,# 7.4 ± 0.3 @
Day 105
Aging Controls 7 276__.6.8 * 1.84-+0.03 0.11 -+0.01 4.6±0.3 *
IM Controls 5 270+_6.7 1.19±0.07 *,# 0.07±0.01 *,# 4.74-0.3 *
I:M+PTH tt 6 279-+6.9 @ 1.26-+0.06 *,# 0.06--.0.01 *,# 5.9--.0.3 *,#.@
Mea +nY.SEM; n: number of ratsin each group; IM: immobilization.
t: immobilized for the Fast 30 days, and then immobilization plus 200 Izg hPTH-(1-38)/kg/day for 15 days.
tt: immobilized for the first 30 days, and then immobilization plus 200 gg hFI_-(1-38)/kg/day for 75 days.
*: p < 0.05 vs basal controls; #: p < 0.05 vs aging controls; @: p < 0.05 vs _ controls.
Table 3. Changes in Bone Mass and Structural Indices of Primary and Secondary
Spongiosa of Proximal Tibial Metaphyses
Groups
Primary. Spongiosa (Zone I) Secondary Spongiosa Zone 17)
Trabecular Trabecular Trabecular Trabecular Trabecular Trabecular
Bone Area Thickness Number Bone Area Thickness Number
(go) (gin) (#/mm) (%) (gm) (#/man)
Day 0
Basal Controls 27.4± 1.2 60.7±1.3 4.5±0.1 16.0±1.1 53.2±1.6 3.0±0.2
Day 30
Aging Controls 26.1 +_.1. t
IM Controls 12.9 ± 1.2 *,#
62.7±2.4
50.2±1.9 *,#
Day 45
Aging Controls 24.0 ± 2.0
IM Controls 10.4 ± 2.0 *,#
IM+PTH t 36.3 ± 1.3 *,#,@
4.2±0.2 17.4±l.4 53.5±0.8
2.6±0.2*,# 12.1±0.9",# 48.8±1.1",#
3.2±0.2
2.5±0.2 #
68.8±2.3 * 3.5±0.2* 15.4±1.3 52.7±1.8 2.9±0.2
49.5±2.7*,# 2.1±0.4",# 10.1±0.5",# 46.6±0.9*,# 2.2±0.1",#
89.4±2.3 *,#,@ 4.1±0.2#,@ _.5±1.8 *,#,@ 73.3±3.4*,#,@ 3.5±0.1 @@
Day 105
Aging Controls 26.8 ± 2.0
IM Controls 10.8 ± 1.2 %#
12M+PTH #t 57.7 ± 2.6 *,#, @
71.9±2.3 * 3.7±0.2 * 17.8±1.0 59.4±1.9" 3.0±0.1
52.9±2.4",# 2.1±0.3 *,# 11.0±0.3 *,# 50.6±1.3 # 2.4±0.I *,#
113.4±4.7",#,@ 5.1±0.3 _@ 61.5±5.6",_@ 172.4±23%#,@ 3.7±0.2 _@
Mean±SEM; n: number of rats in each _oup; IM: immobilization.
t: immobilized for the first 30 days, and then immobilization plus 200 lxg hPTH-(1-38)/kg/day for 15 days.
tt: immobilized for the first 30 days, and then immobilization plus 200 Ixg hPTH-(1-38)/kg/day for 75 days.
*: p < 0.05 vs basal controls; #: p < 0.05 vs aging controls; @: p < 0.05 vs IM controls.
Table 4. Changes in Dynamic I-Iistomorphometry of Secondary Spongiosa of
Proximal Tibial Metaphyses
Groups
Mineral Bone Bone
Eroded Labeling Osteoid Apposition Formation Formation
Perimeter Perimeter Perimeter Rate Rate/TV Rate/BV
(%) (%) (%) (/_rn/d) (%/yr) (%/yr)
Day 0
Basal Controls 0.99.1 24.6±i .9 9.7±1.7 1.8_+0.1 79.4_+4.8 509_+42
Day 30
Aging Controls 1.0-=0.3 16.3-+.2.3* 10.3±1.8 1.3_+0.1* 45.8+10.5 * 260+_50 *
IM 1.49"20.2*,# 15.0"2_1.4* 15.54"2.7_ 0.6__.0 *,# 13.9±0.9 *,# 119±13 *,#
Day 45
Aging Controls 0.89-'0.1 17.69+0.6* 11.7+_2o.7 0.7_4-0.0* 22.6_+1.8 * 150-+13 *
IM controls 1.8±0.3 *,# 17.99+0.7* 12.14-1.4 0.6_+0.0 * 15.0£-_1.8*,# 1504-13 *
]]V[+PTH t 1.I9:-'0.2# 34.3-_o.0 *,#,@ 40.64-2.4 ",#, @ 1.o-_4"0.0",#,@ 83.8±4.9 #,@ 33t4"14 *,#,@
Day 105
Aging Controls 0.89.08 15.4±1.3 * 6.39-20.6* 0.74-0.0 * 19.8+_2.2 * 111±11 *
IM controls 1.0-2-0.13 15.74-1.8 * 7.3_+1.0 0.79+0.0 * 16.14"1.8 * 1354"12 *
IM+PTH "_" 0.9-2-0.12 27.8-+4.3 #,@ 22.3_+6.3#,@ 0.8-+0.0 *,#,@ 50.0-2-6.0 *,#,@ 86.9+14 *,@
Mean_+_SEM;n: number of rots in each group; IM: immobilization.
t: immobilized for the first 30 days, and then immobilization plus 200 _tg hPTH-(1-38)/kg/day for another 15 days;
tt: immobilized for the first 30 days, and then immobilization plus 200 _tg hPTH-(1-38)/kg/day for another 75 days;
*: p < 0.05 vs basal controls; #:.p < 0.05 vs aging controls; @: p < 0.05 vs IM controls.
Age- 6 too. 7 too. 7.5 m.. _).-= too.
Treatment: Basal Control Control Co ntrot
\
.°
30 d 45 d 105 d
\
IM+PTH
• I
.. . .. .
Fig. 1
15 d 75 d
Microphotographs of proximal tibial metaphyses from the age-related controls at 6 (:1), 7
Co), 7.5 (c) and 9.5 (d) months of age, immobihzation controts (LM) at days 30 (e), 45 (0
and 105 (g), and 200 I.tg PTH/kffday treated immobilization proximal tibia2 metaphysis
(IM+PTH) at 15 Ca) and 75 (i) days post-treatment. See text for explanation. X 4..
• . , °
Of r O0,_, .: .....
Fig.2 Nficrophoto_aphsof proximalcibial metaphyses (PTM) and representative trabeculae from
the secondary spongiosa of the age-related controls (A and D), immobilization controls (B
and E), and 200 gg PTH/k_day treated immobilized proximal final metaphysis for 75 days
(C and F). Cancellous bone mass was less and trabeculae were thinner and fewer in the
immobilization control (B) than in age-related control (A). Greater cancellous bone mass
and thicker, denser trabeculae were observed in the primary and secondary spongiosa of
75-day-PTH-treated immobilized PTM (C, F') than in immobilized (B and E) and the age-
re!ated controls (A and D). There was more double Iabeled trabecular surface and a wider
interlabel distance in the 75-day-PTH-treated immobilized PTM (C, F) than in immobilized
(B and E) and the age-related controls (A and D). Xylenol orange (XO), which was given
to all rats at the onset of PTH or vehicle administration, and tetracycline and calcein (DE)
were found in PTH-treated immobilized PTM (F), while only tetracycline and calcein (DL)
car,. be found in the age-related (D) and immobilized t E) controls. Magnifications: A - C,
112: D - F, XlO0.
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Fig.3. Trabecular bone area changes in primary (Zone I, A) and secondary (Zone IT, B) spongiosa
of the age-related controls (a_ng), the immobilization controls (IM) and the PTH-treated
immobilized proximal tibia/metaphysis (IM+PTH). *: p < 0.05 vs. basal; #: p < 0.05 vs.
aging; @: p < 0.05 vs. k-V[.
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Fig.4 Eroded perimeter (A), labeling perimeters (B), mineral apposition rate (C) and bone
formation rate-t.issue referent (D) changes in secondary spongiosa of the age-related
controls (aging), the immobilization controls (IM) and the PTH-r.reated immobilized
proximal tibia[ met,aphysis (IM+PTH). *: p < 0.05 vs. basal; #: p <0.05 vs. aging; @: p <
0.05 vs. 12V[.
